{"id":2859,"date":"2025-02-10T16:57:06","date_gmt":"2025-02-10T13:57:06","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=2859"},"modified":"2025-02-10T16:57:07","modified_gmt":"2025-02-10T13:57:07","slug":"satellos-announces-completed-enrollment-of-phase-1-clinical-trial-of-sat-3247-in-healthy-volunteers","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/tr\/satellos-announces-completed-enrollment-of-phase-1-clinical-trial-of-sat-3247-in-healthy-volunteers\/","title":{"rendered":"Satellos, Sa\u011fl\u0131kl\u0131 G\u00f6n\u00fcll\u00fclerde SAT-3247&#039;nin 1. Faz Klinik Denemesinin Tamamlanan Kayd\u0131n\u0131 Duyurdu"},"content":{"rendered":"<p class=\"wp-block-paragraph\">Kas hastal\u0131klar\u0131 ve bozukluklar\u0131n\u0131n tedavisini iyile\u015ftirmek i\u00e7in yeni k\u00fc\u00e7\u00fck molek\u00fcl terap\u00f6tik yakla\u015f\u0131mlar\u0131 geli\u015ftiren halka a\u00e7\u0131k bir biyoteknoloji \u015firketi olan Satellos Bioscience, bug\u00fcn sa\u011fl\u0131kl\u0131 g\u00f6n\u00fcll\u00fclerde SAT-3247&#039;nin Faz 1 klinik denemesi i\u00e7in d\u00f6rt \u00e7oklu artan doz (MAD) kohortunun tamam\u0131n\u0131n kayd\u0131n\u0131 tamamlad\u0131\u011f\u0131n\u0131 duyurdu.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u201c1. A\u015fama denememizde sa\u011fl\u0131kl\u0131 g\u00f6n\u00fcll\u00fc kayd\u0131n\u0131n tamamlanmas\u0131, dejeneratif hastal\u0131klar\u0131 olan hastalar i\u00e7in d\u00f6n\u00fc\u015ft\u00fcr\u00fcc\u00fc tedaviler geli\u015ftirme misyonumuzda \u00f6nemli bir d\u00f6n\u00fcm noktas\u0131n\u0131 i\u015faret ediyor,\u201d dedi Satellos Kurucu Orta\u011f\u0131 ve CEO&#039;su Frank Gleeson. \u201cSAT-3247&#039;nin, tek ba\u015f\u0131na bir ila\u00e7 veya ek tedavi olarak kullan\u0131ls\u0131n, t\u00fcm DMD hastalar\u0131nda kas rejenerasyonunu ve onar\u0131m\u0131n\u0131 geri kazand\u0131rmak i\u00e7in tasarlanm\u0131\u015f, g\u00fcnde bir kez uygulanan oral bir tedavi olarak yeni, iyi tolere edilen ve daha uygun bir tedavi se\u00e7ene\u011fi oldu\u011funa inan\u0131yoruz. Bu ilerleme, yakla\u015fan b\u00fcy\u00fck bir t\u0131bbi konferansta ilk 1. A\u015fama verilerini sunmam\u0131z i\u00e7in zemin haz\u0131rl\u0131yor ve DMD toplulu\u011funa anlaml\u0131 \u00e7\u00f6z\u00fcmler sunma taahh\u00fcd\u00fcm\u00fcz\u00fc ilerletiyor.\u201d<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">SAT-3247 Duyuru \u00d6zeti<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>\u015eirket, 2025&#039;in 1. \u00e7eyre\u011finde yap\u0131lacak olan \u00f6nemli bir t\u0131bbi toplant\u0131da, \u00e7al\u0131\u015fman\u0131n sa\u011fl\u0131kl\u0131 g\u00f6n\u00fcll\u00fc k\u0131sm\u0131ndaki Tek ve \u00c7oklu Artan Doz (SAD ve MAD) kohortlar\u0131n\u0131n her ikisinden de Faz 1a verilerini bildirme yolunda ilerlemektedir<\/li>\n<\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Denemenin DMD hastalar\u0131ndaki 1b Faz k\u0131sm\u0131, 2025&#039;in 1. \u00e7eyre\u011finde genetik olarak do\u011frulanm\u0131\u015f DMD&#039;li 10 yeti\u015fkin g\u00f6n\u00fcll\u00fcye kadar kay\u0131t yapt\u0131rma niyetiyle devam ediyor.<\/li>\n<\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li>2. A\u015fama IND ba\u015fvurusunun 2025&#039;in 1. \u00e7eyre\u011finin sonuna kadar sunulmas\u0131 bekleniyor<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">SAT-3247 Faz 1 Hakk\u0131nda<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Faz 1 klinik \u00e7al\u0131\u015fmas\u0131 iki bile\u015fenden olu\u015fmaktad\u0131r. \u0130lk bile\u015fende, 72 sa\u011fl\u0131kl\u0131 g\u00f6n\u00fcll\u00fc SAT-3247&#039;nin g\u00fcvenli\u011fini ve farmakokinetik \u00f6zelliklerini de\u011ferlendirmek i\u00e7in k\u00f6r, randomize, plasebo kontroll\u00fc, kademeli, paralel tasar\u0131ml\u0131 bir \u00e7al\u0131\u015fmaya dahil edilmi\u015ftir. Kat\u0131l\u0131mc\u0131lar be\u015f SAD kohortu, d\u00f6rt MAD kohortu ve bir g\u0131da etkisi doz kohortu aras\u0131nda randomize edilmi\u015ftir. \u00c7al\u0131\u015fman\u0131n ikinci bile\u015feni olan Faz 1b k\u0131sm\u0131 \u015fu anda devam etmektedir. Genetik olarak do\u011frulanm\u0131\u015f DMD&#039;li 10&#039;a kadar yeti\u015fkin g\u00f6n\u00fcll\u00fc, hastalarda g\u00fcvenli\u011fi ve farmakokinetik \u00f6zellikleri de\u011ferlendirmek ve olas\u0131 farmakodinamik belirte\u00e7leri ke\u015ffetmek i\u00e7in 28 g\u00fcnl\u00fck, a\u00e7\u0131k etiketli, tek dozluk bir kohorta kaydedilecektir.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">SAT-3247 nedir<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">SAT-3247, Duchenne kas distrofisi (DMD veya Duchenne) ve di\u011fer dejeneratif veya yaralanma durumlar\u0131nda kaybedilen iskelet kas\u0131n\u0131 yenilemek i\u00e7in yeni bir tedavi olarak Satellos taraf\u0131ndan geli\u015ftirilen tescilli, oral k\u00fc\u00e7\u00fck molek\u00fcl bir ila\u00e7t\u0131r. Satellos, distrofin ve ekzon mutasyon durumundan ba\u011f\u0131ms\u0131z olarak DMD i\u00e7in potansiyel bir tedavi olarak SAT-3247&#039;yi ilerletmektedir.<\/p>","protected":false},"excerpt":{"rendered":"<p>Satellos Bioscience, a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, today announced it has completed enrollment of all four multiple-ascending dose (MAD) cohorts for the Phase 1 clinical trial of SAT-3247 in healthy volunteers. \u201cThe completion of healthy volunteer enrollment in our Phase 1 [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2862,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[27],"tags":[171,254,251,252,253],"class_list":["post-2859","post","type-post","status-publish","format-standard","has-post-thumbnail","category-research","tag-canada","tag-frank-gleeson","tag-sat-3247","tag-satellos","tag-satellos-bioscience"],"subtitle":"Satellos, Sa\u011fl\u0131kl\u0131 G\u00f6n\u00fcll\u00fclerde SAT-3247'nin 1. Faz Klinik Denemesi i\u00e7in D\u00f6rt \u00c7oklu Artan Doz Kohortunun Tamamlanm\u0131\u015f Kayd\u0131n\u0131 Duyurdu.","_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/2859","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/comments?post=2859"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/2859\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media\/2862"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media?parent=2859"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/categories?post=2859"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/tags?post=2859"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}